Remedy publishes the financial statements release, two business reviews and the half-year review according to the disclosed annual schedule.
|Silent period and closed window||January 10 – February 9, 2024|
|Financial Statements Release 2023||February 9, 2024|
|Annual Report, Financial Statements and Board of Directors’ Report 2023||Week 12, 2024|
|Silent period and closed window||March 30 – April 29, 2024|
|Annual General Meeting 2024||April 11, 2024|
|Business Review for January-March 2024||April 29, 2024|
|Silent period and closed window||July 10 – August 9, 2024|
|Half-year Financial Report for January-June 2024||August 9, 2024|
|Silent period and closed window||October 2 – November 1, 2024|
|Business Review for January-September 2024||November 1, 2024|
Regularly published financial reports are always preceded by a silent period of 30 days, during which Remedy does not issue statements on the financial position, business operations, markets or prospects.
During the silent period, the senior management of the company does not meet with investors, analysts or other capital market representatives, nor do they give interviews on the financial position of the company.